product name Prasugrel
Description: Prasugrel (also known as CS-747, LY640315) is a novel and potent thienopyridine ADP receptor (P2Y12) antagonist used for the reduction of thrombotic cardiovascular events. Prasugrel was also approved for use in Europe in February 2009. On July 10, 2009, the FDA approved the use of prasugrel for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome who are to be managed with PCI.
References: Biochem Pharmacol. 2007;74:1003-9; Eur J Pharmacol. 2009;612:29-34.
373.44
Formula
C20H20FNO3S
CAS No.
150322-43-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 30 mg/mL (80.3 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)
Synonyms
CS-747, LY640315
other peoduct :
| In Vitro |
In vitro activity: Prasugrel is a novel orally active thienopyridine with faster, higher and more reliable inhibition of platelet aggregation than clopidogrel reflecting its metabolism in vivo to an active metabolite with selective P2Y(12) antagonistic activity. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Prasugrel shows platelet inhibition that was 8.2 times more potent than clopidogrel in WT mice. rasugrel (3 and 10 mg/kg) dose-relatedly and significantly reduces thrombus-mediated cerebral infarction 24 hours after the irradiation in rat models of cerebral and peripheral arterial occlusive diseases. Prasugrel (0.3-3 mg/kg) reduces incidence, total area, and total number of cerebral infarcts in a dose-related manner 24 hours after the vascular injury in an embolic infarction rats model. Prasugrel (0.03-3 mg/kg/day) administered from the day before the lauric acid injection for 11 successive days inhibits the progression of the disease in a dose-related manner in rats with lauric acid-induced peripheral arterial occlusive diseases. Prasugrel administrated in dogs (0.03-0.3 mg/kg/day) and monkeys (0.1 and 0.3 mg/kg/day) once a day for 14 days results in potent, dose-related and cumulative inhibition of ADP-induced platelet aggregation. Prasugrel (0.1-1 mg/kg/day, p.o.) significantly prolongs the time to arterial occlusion and increases the duration of arterial patency in a rat model of electrically-induced arterial thrombosis. |
| Animal model | |
| Formulation & Dosage | |
| References | Biochem Pharmacol. 2007 Oct 1;74(7):1003-9; Eur J Pharmacol. 2009 Jun 10;612(1-3):29-34. |
